Pyrazole and pyrazoline derivatives as antimalarial agents: A key review. 2023

Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
Department of Chemical Sciences, Faculty of Science and Technology, Universiti Kebangsaan Malaysia (UKM), Bangi 43600 Selangor, Malaysia.

Malaria poses a severe public health risk and a significant economic burden in disease-endemic countries. One of the most severe issues in malaria control is the development of drug resistance in malaria parasites. The standard treatment for malaria is artemisinin-combination therapy (ACT). Nevertheless, the Plasmodium parasite's extensive resistance to prior drugs and reduced ACT efficiency necessitates novel drug discovery. The progress in discovering novel, affordable, and effective antimalarial agents is significant in combating drug resistance, and the hybrid drug concept can be used to covalently link two or more active pharmacophores that may act on multiple targets. Pyrazole and pyrazoline derivatives are considered pharmacologically necessary active heterocyclic scaffolds that possess almost all types of pharmacological activities. This review summarized recent progress in antimalarial activities of synthesized pyrazole and pyrazoline derivatives. The studies published since 2000 are included in this systematic review. This review is anticipated to be beneficial for future study and new ideas in searching for rational development strategies for more effective pyrazole and pyrazoline derivatives as antimalarial drugs.

UI MeSH Term Description Entries
D008288 Malaria A protozoan disease caused in humans by four species of the PLASMODIUM genus: PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PLASMODIUM OVALE; and PLASMODIUM MALARIAE; and transmitted by the bite of an infected female mosquito of the genus ANOPHELES. Malaria is endemic in parts of Asia, Africa, Central and South America, Oceania, and certain Caribbean islands. It is characterized by extreme exhaustion associated with paroxysms of high FEVER; SWEATING; shaking CHILLS; and ANEMIA. Malaria in ANIMALS is caused by other species of plasmodia. Marsh Fever,Plasmodium Infections,Remittent Fever,Infections, Plasmodium,Paludism,Fever, Marsh,Fever, Remittent,Infection, Plasmodium,Plasmodium Infection
D010963 Plasmodium falciparum A species of protozoa that is the causal agent of falciparum malaria (MALARIA, FALCIPARUM). It is most prevalent in the tropics and subtropics. Plasmodium falciparums,falciparums, Plasmodium
D011720 Pyrazoles Azoles of two nitrogens at the 1,2 positions, next to each other, in contrast with IMIDAZOLES in which they are at the 1,3 positions.
D004351 Drug Resistance Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration. Resistance, Drug
D005493 Folic Acid Antagonists Inhibitors of the enzyme, dihydrofolate reductase (TETRAHYDROFOLATE DEHYDROGENASE), which converts dihydrofolate (FH2) to tetrahydrofolate (FH4). They are frequently used in cancer chemotherapy. (From AMA, Drug Evaluations Annual, 1994, p2033) Antifolate,Antifolates,Dihydrofolate Reductase Inhibitor,Folic Acid Antagonist,Dihydrofolate Reductase Inhibitors,Folic Acid Metabolism Inhibitors,Acid Antagonist, Folic,Acid Antagonists, Folic,Antagonist, Folic Acid,Antagonists, Folic Acid,Inhibitor, Dihydrofolate Reductase,Inhibitors, Dihydrofolate Reductase,Reductase Inhibitor, Dihydrofolate,Reductase Inhibitors, Dihydrofolate
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000962 Antimalarials Agents used in the treatment of malaria. They are usually classified on the basis of their action against plasmodia at different stages in their life cycle in the human. (From AMA, Drug Evaluations Annual, 1992, p1585) Anti-Malarial,Antimalarial,Antimalarial Agent,Antimalarial Drug,Anti-Malarials,Antimalarial Agents,Antimalarial Drugs,Agent, Antimalarial,Agents, Antimalarial,Anti Malarial,Anti Malarials,Drug, Antimalarial,Drugs, Antimalarial

Related Publications

Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
April 2018, European journal of medicinal chemistry,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
January 2015, Journal of enzyme inhibition and medicinal chemistry,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
November 2014, Pakistan journal of pharmaceutical sciences,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
December 2021, Scientific reports,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
April 2018, Bioorganic chemistry,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
February 2019, European journal of medicinal chemistry,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
April 1963, Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
January 2022, Medicinal chemistry (Shariqah (United Arab Emirates)),
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
February 2011, Bioorganic & medicinal chemistry,
Lekkala Ravindar, and Siti Aishah Hasbullah, and K P Rakesh, and Nurul Izzaty Hassan
May 2019, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!